Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 13/20 | 0.32 |
| ▸ | MAPK14 | Q16539 | 8/20 | 0.32 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.32 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.32 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.31 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL937254 | 1.00 | RAF1 (0.32) | RAF1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL1082972 | 0.88 | NR1I2 (0.37) | NR1I2CYP2E1 | |
| SCHEMBL14645197 | 0.86 | RAF1 (0.35) | RAF1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL936733 | 0.84 | RAF1 (0.32) | RAF1CYP2E1 | |
| SCHEMBL325318 | 0.84 | RAF1 (0.31) | RAF1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL10265133 | 0.84 | NR1I2 (0.31) | RAF1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL325319 | 0.84 | RAF1 (0.31) | RAF1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL15499679 | 0.81 | KDM4E (0.34) | RAF1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL319469 | 0.81 | RAF1 (0.33) | RAF1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL15130828 | 0.81 | ALDH1A1 (0.36) | RAF1MAPK14MAPK13MAPK12MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140030223-A1 | INHIBITORS OF FLAVIVIRIDAE VIRUSES | GILEAD SCIENCES, INC. (US) | 2014-01-30 | — | — | US | disclosed |
| US-8569302-B2 | Inhibitors of flaviviridae viruses | GILEAD SCIENCES, INC. (US) | 2013-10-29 | — | — | US | disclosed |
| EP-2475657-B1 | 5-ALKINYLTHIEN-2-YLCARBOXYLIC ACIDS AS INHIBITORS OF FLAVIVIRIDAE VIRUSES | GILEAD SCIENCES INC (US) | 2013-06-12 | — | — | EP | disclosed |
| US-20110020278-A1 | INHIBITORS OF FLAVIVIRIDAE VIRUSES | GILEAD SCIENCES, INC. (US) | 2011-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140030223-A1 | INHIBITORS OF FLAVIVIRIDAE VIRUSES | HAVCR2, CYP2F1, CYP4F3 | RAF1 1470/4885MAPK14 2109/4885MAPK13 2214/4885 |
| US-20110020278-A1 | INHIBITORS OF FLAVIVIRIDAE VIRUSES | HAVCR2, CYP2F1, CYP4F3 | RAF1 1470/4885MAPK14 2109/4885MAPK13 2214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.